## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.22 indicates fundamental undervaluation. Quality metrics strong (ROE 136%, ROA 12%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($465.68)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. HCA Healthcare (NYSE: HCA) appoints Virginia Tenpenny to lead community engagement**
- Source: Stock Titan | 20251209T133231 | Bullish | Relevance: 99%
- HCA Healthcare has appointed Virginia Tenpenny as its new Vice President of Community Engagement, effective January 12, 2026. Tenpenny, who has over two decades of experience in corporate community impact, will lead the company's community engagement strategy, succeeding the retiring Joanne Pulles. This role oversees social and charitable investments, colleague giving, community outreach, and strategic partnerships.

**2. Natixis Has $21.56 Million Position in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251209T130812 | Somewhat-Bullish | Relevance: 99%
-  Natixis reduced its stake in HCA Healthcare, Inc. by 4.3% in Q2, now holding 56,272 shares valued at $21.56 million. Other institutional investors have also adjusted their positions, and an insider recently sold a significant number of shares. HCA Healthcare reported strong quarterly earnings, surpassing analyst estimates, and announced a quarterly dividend.

**3. California Public Employees Retirement System Has $124.64 Million Stock Position in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251208T094854 | Bullish | Relevance: 98%
-  The California Public Employees' Retirement System (CalPERS) recently reduced its HCA Healthcare (NYSE:HCA) holdings by 5.4%, but still maintains a significant position worth approximately $124.64 million. This move comes as other institutional investors, such as Norges Bank and Price T Rowe Associates Inc. MD, have either initiated or significantly boosted their stakes in the company. HCA Healthcare reported strong Q3 earnings, surpassing analyst estimates, and announced a quarterly dividend, indicating healthy financial performance and a commitment to shareholder returns.

**4. HCA Healthcare Names Virginia Tenpenny Vice President of Community Engagement**
- Source: Business Wire | 20251209T130813 | Bullish | Relevance: 98%
-  HCA Healthcare, Inc. announced Virginia Tenpenny as its new Vice President of Community Engagement, effective January 12, 2026. Tenpenny will lead strategies for social and charitable investments, colleague giving, community outreach, and strategic partnerships, bringing over two decades of corporate community impact experience. She succeeds Joanne Pulles, who is retiring after 26 years with HCA Healthcare, during which she established the HCA Healthcare Hope Fund.

**5. HCA Healthcare to give $4.8m to support Pepperdine University’s nursing school**
- Source: Yahoo | 20251208T101200 | Bullish | Relevance: 98%
-  HCA Healthcare has committed $4.8 million to Pepperdine University’s School of Nursing to help address the national nursing shortage. This investment will support the development of a new 30,000-square-foot facility on the Calabasas campus, featuring advanced simulation laboratories. Students will also have opportunities for clinical rotations at HCA Healthcare’s Los Robles Regional Medical Center.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Wells Fargo | $431 | $412 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.22 suggests fair value with growth premium. Forward P/E 16.4x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $114.3B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.22 |
| Forward P/E | 16.4 |
| Current P/E | 17.7 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.6% over 5 days). Below STRENGTH zone by 6.1pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.1%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-3.20), momentum weakening. RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.08% (CS: 44) | Weak |
| RSI_14 | 55.6 | Neutral |
| MACD Histogram | -3.20 | Bearish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.060x | Above |
| vs SMA200 | 1.254x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $488.50
- **Stop Loss:** $465.68 (4.7% risk)
- **Target:** $534.14 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 13
- **Position Value:** $6,350.50
- **Portfolio %:** 6.35%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*